Overview

Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes

Status:
Completed
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
No head to head comparisons between exenatide once weekly and liraglutide have been performed. Therefore, the purpose of this study is to compare exenatide once weekly to once-daily liraglutide with regard to HbA1c, body weight, subject-reported outcomes, and other clinical benefits. The study includes a 26-week treatment period and a safety follow-up visit 10 weeks after the final study drug dose.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Eli Lilly and Company
Treatments:
Exenatide
Liraglutide